

CITATION REPORT

List of articles citing

The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells

DOI: 10.1016/0192-0561(93)90052-Z
International Journal of Immunopharmacology, 1993,
15, 409-13.

Source: <https://exaly.com/paper-pdf/23764194/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
190	Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. 1993 , 26, 259-64		88
189	Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. 1994 , 102 Suppl 10, 79-84		19
188	Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents. 1994 , 185-194		16
187	Cyclic nucleotide phosphodiesterases in the human lung. 1994 , 172, 129-46		35
186	Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. <i>International Journal of Immunopharmacology</i> , 1994 , 16, 805-16		106
185	Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. <i>Biochemical Pharmacology</i> , 1994 , 47, 781-8	6	92
184	Chapter 8. Emerging Opportunities in the Treatment of Asthma and Allergy. 1994 , 29, 73-81		4
183	Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Anti-inflammatory patent highlights: January-July 1994. 1995 , 5, 127-156		2
182	Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. 1995 , 25, 147-53		80
181	Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. 1995 , 44, 400-5		32
180	Interleukin-1-induced IL-8 and IL-6 gene expression and production in human mesangial cells is differentially regulated by cAMP. 1995 , 48, 1767-77		26
179	The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. 1995 , 1, 244-8		306
178	The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 605-10		29
177	The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 793-803		30
176	Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. 1995 , 92, 3601-5		156
175	Pulmonary TNF α is a critical mediator in Adult Respiratory Distress Syndrome. 1995 , 2, 189-193		1
174	Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. <i>European Journal of Pharmacology</i> , 1995 , 281, 69-74	5.3	32

173	Brain injury and inflammation. A putative role of TNF alpha. 1995 , 765, 62-71; discussion 98-9		48
172	Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. 1995 , 115, 39-46		71
171	Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. 1996 , 117, 1530-4		33
170	Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. 1996 , 118, 649-58		95
169	Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. 1996 , 64, 193-200		94
168	Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis. <i>European Journal of Pharmacology</i> , 1996 , 299, 229-33	5.3	13
167	Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. <i>Biochemical Pharmacology</i> , 1996 , 51, 949-56	6	92
166	Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 2-9	8.3	45
165	Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors. 1996 , 5, 425-8		7
164	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The current status and future prospects for biological targeted therapies for rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 1996 , 5, 819-828	5.9	4
163	Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. 1996 , 45, 125-132		2
162	Chapter 8. Chronic Pulmonary Inflammation and Other Therapeutic Applications of PDE IV Inhibitors. 1996 , 71-80		13
161	Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. 1996 , 318 (Pt 2), 425-36		38
160	Phosphodiesterase type IV inhibitors. 1996 , 33, 1-52		38
159	The role of inflammation and cytokines in brain injury. 1996 , 20, 445-52		333
158	Inhibition of myofibroblastic transformation of cultured rat hepatic stellate cells by methylxanthines and dibutyl cAMP. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 1022-9	4	31
157	The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. 1996 , 29, 183-90		11
156	Vesnarinone is a selective inhibitor of macrophage TNF(alpha) release. <i>International Journal of Immunopharmacology</i> , 1996 , 18, 371-8		11

155	Experimental immunotherapies for multiple sclerosis. 1996 , 18, 1-24		26
154	Immunomodulation: an important concept in modern anaesthesia. 1996 , 51, 465-73		82
153	Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. 1996 , 26 Suppl 2, 2-9		17
152	Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. 1996 , 271, 20828-35		279
151	Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. 1996 , 6, 291-9		30
150	Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. 1997 , 64, 283-350		173
149	Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. <i>Biochemical Pharmacology</i> , 1997 , 54, 613-7	6	38
148	Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. <i>European Journal of Pharmacology</i> , 1997 , 321, 231-9	53	26
147	Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. 1997 , 99, 28-37		27
146	The effect of rolipram on the production of cytokines in HTLV-I infected cell lines and peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy (HAM). 1997 , 148, 87-94		5
145	Importance of interferon-gamma in protective immunity against <i>Hymenolepis nana</i> cysticercoids derived from challenge infection with eggs in BALB/c mice. 1997 , 27, 1437-43		6
144	Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. 1997 , 79, 54-61		67
143	Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. 1997 , 825, 179-93		184
142	In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. 1997 , 121, 221-31		114
141	Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. 1997 , 121, 743-50		24
140	Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. 1997 , 122, 1483-9		80
139	Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. 1997 , 52, 917-25		93
138	Advances in antiarthritic therapeutics. 1997 , 2, 427-435		15

137	Taming TNF: strategies to restrain this proinflammatory cytokine. 1997 , 18, 487-92		237
136	Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells. 1997 , 27, 816-823		11
135	Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. 1998 , 123, 1031-8		63
134	Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. 1998 , 28, 135-60		25
133	Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. <i>International Journal of Immunopharmacology</i> , 1998 , 20, 685-95		60
132	Pharmacological modulation of cytokine action and production through signaling pathways. 1998 , 9, 239-57		27
131	Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. 1998 , 157, 351-70		595
130	1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 821-35	8.3	126
129	Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. 1998 , 24, 593-614		54
128	Emerging therapeutic targets in focal stroke and brain trauma: cytokines and the brain inflammatory response to injury. 1998 , 2, 17-39		4
127	Inflammatory bowel diseases: a new wave of therapy. 1998 , 8, 785-818		2
126	Effects of phosphodiesterase inhibitors on secretions of human monokines. 1998 , 47, 219-224		2
125	Enantiodivergent Synthesis of (R)- and (S)-Rolipram. 1998 , 3, 107-119		31
124	Pentoxifylline attenuates reperfusion injury in skeletal muscle after partial ischemia. 1998 , 274, H1435-42		13
123	Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. 1999 , 277, H543-50		21
122	Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. 1999 , 13, 251-60		58
121	Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. <i>Clinical and Experimental Immunology</i> , 1999 , 118, 315-21	6.2	19
120	Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. 1999 , 55, 29-62		215

119	Pentoxifylline decreases neutrophil respiratory bursts in patients with stable angina. 1999 , 13, 237-42		4
118	Inflammatory mediators and stroke: new opportunities for novel therapeutics. 1999 , 19, 819-34		783
117	Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. <i>European Journal of Pharmacology</i> , 1999 , 367, 399-404	5.3	7
116	Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats?. 1999 , 32, 41-5		7
115	Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD40 signals. 1999 , 42, 1917-26		22
114	The role of cytokines in cancer cachexia. 1999 , 19, 223-48		154
113	Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes. 1999 , 62, 441-4		89
112	Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo. 2000 , 27, 787-92		8
111	Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. 2000 , 47, 127-62		216
110	Advances in the therapy of rheumatoid arthritis with biological agents. <i>Expert Opinion on Emerging Drugs</i> , 2000 , 5, 367-384		1
109	Therapeutic potential of anti-inflammatory drugs in focal stroke. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 2281-306	5.9	67
108	Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. 2000 , 157, 99-103		4
107	Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. 2000 , 27, 811-7		82
106	A review of standard and novel therapies in Crohn's disease. 2000 , 10, 1021-1033		
105	Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?. 2000 , 13, 87-94		15
104	The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. 2000 , 37, 39-51		65
103	Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. 2000 , 59, 193-212		127
102	Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. <i>Pulmonary Pharmacology and Therapeutics</i> , 2001 , 14, 157-64	3.5	49

101	Targeting tumour necrosis factor in the treatment of rheumatoid arthritis. 2001 , 15, 139-49		18
100	Cancer cachexia: a therapeutic approach. 2001 , 21, 83-101		61
99	Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. 2001 , 15, 1564-71		21
98	Design of rolipram-loaded nanoparticles: comparison of two preparation methods. 2001 , 71, 297-306		58
97	Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. <i>European Journal of Pharmacology</i> , 2001 , 417, 11-8	5.3	11
96	Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma. <i>European Journal of Pharmacology</i> , 2001 , 429, 335-44	5.3	10
95	Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 300, 559-66	4.7	91
94	Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. 2002 , 99, 7628-33		294
93	Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. <i>Pulmonary Pharmacology and Therapeutics</i> , 2002 , 15, 7-15	3.5	12
92	Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. <i>Neuropharmacology</i> , 2002 , 42, 262-9	5.5	80
91	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. 2002 , 188, 53-8		1
90	Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). <i>Biochemical Pharmacology</i> , 2002 , 63, 797-807	6	33
89	Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. <i>Biochemical Pharmacology</i> , 2002 , 63, 1527-35	6	24
88	Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1471-7	6.3	17
87	Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. <i>Biochemical Pharmacology</i> , 2003 , 66, 801-7	6	15
86	Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats. <i>European Journal of Pharmacology</i> , 2003 , 465, 133-9	5.3	11
85	Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003 , 13, 2347-50	2.9	3
84	Rolipram inhibits polarization and migration of human T lymphocytes. <i>Journal of Investigative Dermatology</i> , 2003 , 121, 81-7	4.3	14

83	Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats. <i>Pathophysiology</i> , 2003 , 9, 195-200	1.8	6
82	The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 549-56	4.7	33
81	Antibiotic cyclic AMP signaling by "primed" leukocytes confers anti-inflammatory cytoprotection. <i>Journal of Leukocyte Biology</i> , 2003 , 74, 908-15	6.5	15
80	Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1106-15	4.3	45
79	Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2004 , 19, 475-80	5.6	4
78	Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine] a potent and selective phosphodiesterase 4 inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 310, 752-60	4.7	18
77	Conventional protein kinase C and atypical protein kinase Czeta differentially regulate macrophage production of tumour necrosis factor-alpha and interleukin-10. <i>Immunology</i> , 2004 , 112, 44-53	7.8	41
76	The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. <i>Respiratory Research</i> , 2004 , 5, 4	7.3	20
75	PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. <i>Trends in Pharmacological Sciences</i> , 2004 , 25, 430-6	13.2	72
74	Interference of arachidonic acid and its metabolites with TNF-alpha release by ochratoxin A from rat liver. <i>Toxicology</i> , 2005 , 208, 335-46	4.4	20
73	Specific type IV phosphodiesterase inhibitor ameliorates thioacetamide-induced liver injury in rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005 , 20, 135-40	4	9
72	Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1097-102	4	7
71	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 1609-19	5.6	35
70	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 2036-46	5.6	75
69	The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2005 , 18, 49-54	3.5	28
68	Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 346, 339-44	3.4	17
67	Medicinal Chemistry of PDE4 Inhibitors. 2006 ,		
66	Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. <i>Brain Pathology</i> , 2000 , 10, 95-112	6	497

65	Immunotoxic activity of ochratoxin A. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006 , 29, 79-90	1.4	131
64	Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis. <i>Journal of Bone and Mineral Metabolism</i> , 2006 , 24, 260-5	2.9	4
63	Nimesulide-induced antipyresis in rats involves both cyclooxygenase-dependent and independent mechanisms. <i>European Journal of Pharmacology</i> , 2006 , 543, 181-9	5.3	5
62	Role of inflammation and cellular stress in brain injury and central nervous system diseases. <i>Clinical Neuroscience Research</i> , 2006 , 6, 329-356		15
61	Cytokines as mediators and targets for cancer cachexia. <i>Cancer Treatment and Research</i> , 2006 , 130, 199-217	3.17	44
60	Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. <i>Current Topics in Developmental Biology</i> , 2006 , 75, 225-59	5.3	37
59	History of development of TNF inhibitors. 2006 , 9-22		4
58	Pharmacology of Inflammation. 2007 ,		
57	Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. <i>European Journal of Pharmacology</i> , 2007 , 559, 219-26	5.3	18
56	Mitigation of stress-induced gastric mucosal lesions by a specific type IV phosphodiesterase inhibitor. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 711-6	4	2
55	Determination of the kinetic and equilibrium parameters of the n-boc-rolipram enantiomers on a chiral stationary phase by high performance liquid chromatography. <i>Chemical Engineering Journal</i> , 2007 , 133, 151-156	14.7	10
54	Expression profiles of phosphodiesterase 4D splicing variants in osteoblastic cells. <i>Journal of Bone and Mineral Metabolism</i> , 2008 , 26, 152-8	2.9	3
53	Purification of n-boc-Rolipram racemate on chiral stationary phase using simulated moving bed chromatography under linear conditions. <i>Biochemical Engineering Journal</i> , 2008 , 40, 526-536	4.2	9
52	COX inhibitors downregulate PDE4D expression in a clinical model of inflammatory pain. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 39-42	6.1	9
51	Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. <i>Clinical and Experimental Immunology</i> , 1995 , 100, 126-32	6.2	102
50	Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. <i>Clinical and Experimental Immunology</i> , 1995 , 99, 461-6	6.2	84
49	Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008 , 1782, 271-9	6.9	18
48	Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, G718-24	5.1	51

47	Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats. <i>Pancreas</i> , 2010 , 39, 639-45	2.6	9
46	Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R107	5.7	93
45	A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. <i>Journal of Neurotrauma</i> , 2011 , 28, 1035-49	5.4	32
44	Phosphodiesterase inhibitors: history of pharmacology. <i>Handbook of Experimental Pharmacology</i> , 2011 , 1-46	3.2	27
43	Why do we need new treatments for rheumatoid arthritis?. <i>Journal of Pharmacy and Pharmacology</i> , 1998 , 50, 357-69	4.8	17
42	Small molecular therapies for rheumatoid arthritis: where do we stand?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 23-31	5.9	6
41	Practical Large-Scale Preparation of (R)-Rolipram Using Chiral Nickel Catalyst. <i>Synthetic Communications</i> , 2012 , 42, 3288-3295	1.7	7
40	Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury. <i>Glia</i> , 2012 , 60, 1839-59	9	57
39	The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. <i>PLoS ONE</i> , 2013 , 8, e56867	3.7	16
38	Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 2221-38	4.4	135
37	The importance of glia in dealing with stress. <i>Psychiatric Clinics of North America</i> , 2014 , 37, 679-705	3.1	3
36	3,5,6,7,8,3',4'-Heptamethoxyflavone, a citrus flavonoid, on protection against memory impairment and neuronal cell death in a global cerebral ischemia mouse model. <i>Neurochemistry International</i> , 2014 , 70, 30-8	4.4	36
35	Modulation in the expression of SHP-1, SHP-2 and PTP1B due to the inhibition of MAPKs, cAMP and neutrophils early on in the development of cerulein-induced acute pancreatitis in rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 192-201	6.9	9
34	3,5,6,7,8,3',4'-heptamethoxyflavone, a citrus polymethoxylated flavone, attenuates inflammation in the mouse hippocampus. <i>Brain Sciences</i> , 2015 , 5, 118-29	3.4	21
33	An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 10113-10126	8.3	19
32	Changes in the expression of LIMP-2 during cerulein-induced pancreatitis in rats: Effect of inhibition of leukocyte infiltration, cAMP and MAPKs early on in its development. <i>International Journal of Biochemistry and Cell Biology</i> , 2016 , 72, 109-117	5.6	4
31	Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine. <i>Pediatric Research</i> , 2016 , 80, 101-9	3.2	12
30	Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 1338-1344	2.9	3

29	MKP-1 negative regulates Staphylococcus aureus induced inflammatory responses in Raw264.7 cells: roles of PKA-MKP-1 pathway and enhanced by rolipram. <i>Scientific Reports</i> , 2017 , 7, 12366	4.9	3
28	Treatment of endotoxaemia and septicaemia in the equine patient. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017 , 40, 1-15	1.4	12
27	Novel Intra-cellular Targeting Agents in Rheumatic Disease. 2017 , 1044-1060		1
26	Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF- α production. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 24-30	2.9	13
25	Enantioselective conjugate addition of an α -dithioacetonitrile with nitroalkenes using chiral bis(imidazoline)-Pd complexes. <i>Chemical Communications</i> , 2019 , 55, 5391-5394	5.8	14
24	Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?. <i>Pharmacology & Therapeutics</i> , 2020 , 208, 107475	13.9	17
23	Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review. <i>European Journal of Medicinal Chemistry</i> , 2021 , 226, 113867	6.8	3
22	Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1999 , 53, 193-229		76
21	Tumor Necrosis Factor and Other Cytokines in Septic Syndrome. <i>Update in Intensive Care and Emergency Medicine</i> , 1994 , 107-121		2
20	Interaction of PDE4 Inhibitors with Enzymes and Cell Functions. 1996 , 111-126		7
19	Characterization of Different States of PDE4 by Rolipram and RP 73401. 1996 , 173-184		1
18	Molecular Aspects of Inhibitor Interaction with PDE4. 1996 , 185-207		4
17	Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 769-76	3.1	11
16	Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. <i>Journal of Virology</i> , 1998 , 72, 4712-20	6.6	49
15	Locally produced tumor necrosis factor-alpha mediates interleukin-2-induced lung injury. <i>Circulation Research</i> , 1996 , 78, 329-36	15.7	39
14	Recent developments in the treatment of rheumatoid arthritis with targeted biological agents. <i>Expert Opinion on Emerging Drugs</i> , 1997 , 2, 269-286		1
13	Phosphodiesterase inhibitors for respiratory diseases. 2000 , 223-253		
12	Tumor necrosis factor (TNF) inhibition in the treatment of vasculitis. 2001 , 41-63		

11	Insights into the Physiological Functions of PDE4 from Knockout Mice. 2006 ,		
10	Experimental immunotherapies for multiple sclerosis. 1996 , 119-142		
9	Effect of the type IV phosphodiesterase inhibitor Ro 20-1724 on catecholamine-induced alterations in regional vascular resistance and regional blood flow. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 840-53	3.1	
8	Protective effects of rolipram on endotoxic cardiac dysfunction via inhibition of the inflammatory response in cardiac fibroblasts. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 242	2.3	1
7	Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , 2004 , 9, 103-11		33
6	Antiallodynamic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury. <i>Neuropharmacology</i> , 2021 , 205, 108909	5.5	0
5	In Silico Drug Repurposing for Anti-Inflammatory Therapy: Virtual Search for Dual Inhibitors of Caspase-1 and TNF-Alpha.. <i>Biomolecules</i> , 2021 , 11,	5.9	1
4	Suppression of TNF- β production in human mononuclear cells by an adenosine kinase inhibitor. 2000 , 68, 97-103		1
3	Paradoxical Effects of Adenovirus-Mediated Blockade of TNF Activity in Murine Collagen-Induced Arthritis. 1999 , 163, 1000-1009		13
2	Regulation of IL-15-Stimulated TNF- β Production by Rolipram. 1999 , 163, 2836-2843		7
1	Selective Pharmacologic Inhibition of Murine and Human IL-12-Dependent Th1 Differentiation and IL-12 Signaling. 1999 , 163, 6567-6574		7